Evidence map›Paper›PMID 36831648›Full record

ReviewCancers2023

Extracellular Vesicles in Liquid Biopsies as Biomarkers for Solid Tumors.

Barnabas Irmer, Suganja Chandrabalan, Lukas Maas, Annalen Bleckmann, Kerstin Menck

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 2 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. A Dual-Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Barnabas IrmerDepartment of Medicine A, Hematology, Oncology, and Pneumology, University of Münster, 48149 Munster, Germany.
Suganja ChandrabalanDepartment of Medicine A, Hematology, Oncology, and Pneumology, University of Münster, 48149 Munster, Germany.
Lukas MaasDepartment of Medicine A, Hematology, Oncology, and Pneumology, University of Münster, 48149 Munster, Germany.
Annalen BleckmannDepartment of Medicine A, Hematology, Oncology, and Pneumology, University of Münster, 48149 Munster, Germany.
Kerstin MenckDepartment of Medicine A, Hematology, Oncology, and Pneumology, University of Münster, 48149 Munster, Germany.ORCID 0000-0002-8188-0163
University of Münster · DE

Funding

Deutsche Forschungsgemeinschaft 424252458Else Kröner-Fresenius-Stiftung 2019_A162Innovative Medical research (IMF) project of the Medical Faculty, University of Münster ME 12 19 14Volkswagen Foundation ZN3424
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are secreted by all living cells and are ubiquitous in every human body fluid. They are quite heterogeneous with regard to biogenesis, size, and composition, yet always reflect their parental cells with their cell-of-origin specific cargo loading. Since numerous studies have demonstrated that EV-associated proteins, nucleic acids, lipids, and metabolites can represent malignant phenotypes in cancer patients, EVs are increasingly being discussed as valuable carriers of cancer biomarkers in liquid biopsy samples. However, the lack of standardized and clinically feasible protocols for EV purification and characterization still limits the applicability of EV-based cancer biomarker analysis. This review first provides an overview of current EV isolation and characterization techniques that can be used to exploit patient-derived body fluids for biomarker quantification assays. Secondly, it outlines promising tumor-specific EV biomarkers relevant for cancer diagnosis, disease monitoring, and the prediction of cancer progression and therapy resistance. Finally, we summarize the advantages and current limitations of using EVs in liquid biopsy with a prospective view on strategies for the ongoing clinical implementation of EV-based biomarker screenings.

Indexed as

biomarkercancerextracellular vesiclesliquid biopsy

Identifiers

PMID36831648
PMCPMC9953862
OpenAlexW4321376294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.